Announced
Completed
BioNTech completed the acquisition of AexeRNA Therapeutics for $1bn.
Synopsis
BioNTech, a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, completed the acquisition of AexeRNA Therapeutics, a company developing mRNA therapeutics utilizing its proprietary next-generation programmable and highly potent Lipid Nanoparticle nucleic acid delivery system, for $1bn.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.